Wnt signalling in development and disease. Max Delbruck Center for Molecular Medicine Meeting on Wnt Signaling in Development and Disease. EMBO Rep. 2008; 9: 134–138. , , .
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107: 513–523. , , , et al.
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002; 70: 11–19. , , , et al.
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA. 2005; 102: 3324–3329. , , , et al.
Wnt gene expression in the post-natal growth plate: regulation with chondrocyte differentiation. Bone. 2007; 40: 1361–1369. , , , .
Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133: 3231–3244. , .
Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J Cell Physiol. 2006; 208: 77–86. , , , , .
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8: 751–764. , , , et al.
Beyond Wnt inhibition: new functions of secreted frizzled-related proteins in development and disease. J Cell Sci. 2008; 121: 737–746. , , , , .
The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem. 2005; 96: 1212–1230. , , , et al.
The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004; 18: 1222–1237. , , , et al.
Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol. 2007; 210: 352–357. , , , , .
Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res. 2004; 19: 1873–1881. , , , et al.
A DNA microarray analysis of chemokine and receptor genes in the rat dental follicle: role of secreted frizzled-related protein-1 in osteoclastogenesis. Bone. 2007; 41: 266–272. , .
A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein (SFRP)-1 stimulates bone formation. J Bone Miner Res. 2007; 22: S4. , , , , , .
Highly efficient modification of bacterial artificial chromosomes (BACs) using novel shuttle vectors containing the R6Kγ origin of replication. Genome Res. 2002; 12: 1992–1998 . , , , .
Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res. 2006; 21: 466–476. , , , et al.
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008; 58: 1674–1686. , , , , , .
Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum. 2008; 58: 3485–3497. , , , et al.
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005; 280: 21162–21168. , , , et al.
Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. Cell Metab. 2005; 2: 344–345. , , .
Eating bone or adding it: the Wnt pathway decides. Nat Med. 2007; 13: 133–134. , .
Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007; 13: 156–163. , , , et al.
PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004; 19: 235–244. , , , et al.
LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone. 2005; 37: 770–775. , , , et al.
Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am J Hum Genet. 2004; 74: 866–875. , , , et al.
Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men. Bone. 2007; 40: 587–596. , , , et al.
Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008; 299: 1277–1290. , , , et al.
The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006; 281: 23698–23711. , , , et al.
Bone biomechanical properties in LRP5 mutant mice. Bone. 2004; 35: 162–169. , , , et al.
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res. 2003; 18: 960–974. , , , et al.
The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol. 2004; 24: 4677–4684. , , , et al.
Anabolic actions of PTH in the skeletons of animals. J Musculoskelet Neuronal Interact. 2001; 2: 33–47. .
PTH receptors and apoptosis in osteocytes. J Musculoskelet Neuronal Interact. 2002; 2: 245–251. .
Apoptosis mediated by activation of the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein (PTHrP). Mol Endocrinol. 2000; 14: 241–254. , , , .
Role of PTHrP and PTH-1 receptor in endochondral bone development. Front Biosci. 1998; 3: d795–d803. , .
Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 2005; 95: 1178–1190. , , , et al.
Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006; 147: 2583–2590. , , , et al.
Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskel Neuronal Interact. 2006; 6: 358–359. .
SOST is a target gene for PTH in bone. Bone. 2005; 37: 148–158. , .
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008; 3: e2942. , , , et al.
PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res. 2007; 22: 394–402. , , , et al.
Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008; 22: 2968–2979. , , , et al.
Advances in bone biology and new treatments for bone loss. Maturitas. 2008; 60: 65–69. .
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89: 309–319. , , , et al.
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135: 825–837. , , , et al.